<DOC>
	<DOCNO>NCT00630708</DOCNO>
	<brief_summary>The primary aim present study ass safety combine treatment benazepril ( ACE inhibitor ) losartan ( ARB ) non-diabetic patient advance renal insufficiency .</brief_summary>
	<brief_title>Safety Dual Blockage Rennin-angiotensin System Patients With Advanced Renal Insufficiency</brief_title>
	<detailed_description>Interruption renin-angiotensin systerm ( RAS ) angiotensin-converting enzyme ( ACE ) inhibitor angiotensin II receptor blocker ( ARB ) slow progression chronic renal insufficiency presence absence diabetes . Even advance chronic renal insufficiency ( stage 4 CKD ) , ACE inhibitor ARBs still provide renoprotection . Some clinical study show dual RAS blockage seem enhance antiproteinuric effect compare single-agent ACE inhibitor ARB improve renal survival . However , one randomize control trial investigate renoprotection combine ACE inhibitor ARB mild moderate chronic renal insufficiency ( mean creatinine value 2.9mg/dl ) , incidence hyperkalemia increase combination therapy compare monotherapy . Although increase hyperkalemia statistical significant , suggested combination treatment ACEI ARB might increase incidence hyperkalemia patient advance renal insufficiency . However , still undetermined whether combination treatment ACE inhibitor ARB safe ACE inhibitor ARB monotherapy advance non-diabetic chronic renal insufficiency ( stage 4 CKD ) . The primary aim present study ass safety combine treatment benazepril ( ACE inhibitor ) losartan ( ARB ) non-diabetic patient advance renal insufficiency .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Benazepril</mesh_term>
	<criteria>1 . Serum creatinine concentration 3.0 5.0 mg per deciliter ( 265 442 µmol/L ) 2 . Creatinine clearance 15 30 ml per minute per 1.73m2 , variation less 30 percent three month screen evaluation 3. nondiabetic renal disease 4 . Persistent heavy proteinuria ( defined urinary protein excretion 0.3g per day three month without evidence urinary tract infection overt heart failure [ New York Heart Association class Ⅲ Ⅳ ] ) 5. receive ACE inhibitor ARBs least two week screen 1 . No history allergic reaction drug , especially ACE inhibitor and/or ARBs 2 . Hyperor hypokalemia ( serum potassium concentration 5.6 mmol per liter more，or 3.5 mmol per liter le ) 3 . Malignant hypertension ( blood pressure &gt; 180/120 mm Hg ) blood pressure &lt; 110mm Hg without antihypertensive treatment 4 . Treatment drug affect serum potassium diuretic , β2 receptor blocker et al . 5 . Treatment corticosteroid , nonsteroidal antiinflammatory drug , immunosuppressive drug , especially ciclosporin A 6 . Myocardial infarction cerebrovascular accident year precede trial 7 . Nephrotic syndrome ( albuminaemia le 25 g/L ) 8 . Renovascular disease connectivetissue disease 9 . Obstructive uropathy 10 . Immediate need dialysis 11 . Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Renal insufficiency</keyword>
	<keyword>Benazepril</keyword>
	<keyword>Losartan</keyword>
	<keyword>combination treatment</keyword>
	<keyword>Safety</keyword>
</DOC>